Company profile: Avaxia Biologics
1.1 - Company Overview
Company description
- Provider of orally delivered, gut-targeted antibody therapeutics using a proprietary platform, including Avaximab-TNF for local intestinal anti-TNF action in inflammatory bowel disease; AVX-470, an oral anti-TNF polyclonal antibody from bovine milk evaluated in Phase 1b for ulcerative colitis; and the Avaximabs platform for recombinant antibodies that withstand the GI environment and act locally.
Products and services
- Avaximabs: Architects a GI-stable antibody platform for developing recombinant, gut-targeted therapeutics that endure the gastrointestinal environment and act locally to modulate intestinal inflammation
- AVX-470: Produces an oral, Phase 1b-evaluated polyclonal anti-TNF antibody derived from bovine milk for treating ulcerative colitis, leveraging gut delivery of antibodies
- Avaximab-TNF: Engineers a recombinant, orally administered anti-TNF antibody with intestinal-local action to treat inflammatory bowel disease by acting directly in the intestines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avaxia Biologics
VBI Vaccines
HQ: United States
Website
- Description: Provider of novel biopharmaceutical technologies that seek to expand vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VBI Vaccines company profile →
Atreca
HQ: United States
Website
- Description: Provider of antibody discovery and development technologies that identify antibodies generated during immune responses from patient blood without prior antigen knowledge. Offers the Atreca Discovery Platform to generate clinical candidates and IRC single-B-cell sequencing; develops antibody-based oncology therapeutics; and partners in cancer immunotherapy, infectious disease, and autoimmune disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atreca company profile →
CellPoint
HQ: The Netherlands
Website
- Description: Provider of point-of-care CAR-T therapy solutions enabling clinicians to retarget patient immune cells to treat hematological malignancies, with a 6-day manufacturing process powered by the proprietary xCellit real-time monitoring software system that allows for 1 week vein-to-vein time, making therapies more affordable and accessible.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellPoint company profile →
Osivax
HQ: France
Website
- Description: Provider of immunotherapy vaccines powered by the oligoDOM self-assembling nanoparticle platform to elicit potent T- and B-cell responses and enable universal vaccines against mutating pathogens. Pipeline includes OVX836, a universal influenza A vaccine targeting nucleoprotein; OVX033, a universal sarbecovirus vaccine targeting nucleocapsid; and PANHPVAX, a pan-strain HPV vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Osivax company profile →
Alteris Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of therapeutics and vaccines, leveraging alternative splice forms and disease-specific splice variants to design truly disease-specific drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alteris Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avaxia Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avaxia Biologics
2.2 - Growth funds investing in similar companies to Avaxia Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avaxia Biologics
4.2 - Public trading comparable groups for Avaxia Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →